Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry
Authors:
- Vladimir TolmachevVladimir Tolmachev
- Mikaela FriedmanMFMikaela Friedman
- Mattias SandströmMSMattias Sandström
- Tove L.J. ErikssonTETove L.J. Eriksson
- Daniel RosikDRDaniel Rosik
- Monika HodikMHMonika Hodik
- Stefan StåhlSSStefan Ståhl
- Fredrik Y. FrejdFFFredrik Y. Frejd
- Anna OrlovaAOAnna Orlova
Open Access
- 21 January 2009
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 50 (2) , 274-283
Abstract
Noninvasive detection of epidermal growth factor receptor (EGFR) expression in malignant tumors by radionuclide molecular imaging may provide diagnostic information influencing patient management. The aim of this study was to evaluate a novel EGFR-targeting protein, the ZEGFR:1907 Affibody molecule, for radionuclide imaging of EGFR expression, to determine a suitable tracer format (dimer or monomer) and optimal label. Methods: An EGFR-specific Affibody molecule, ZEGFR:1907, and its dimeric form, (ZEGFR:1907)2, were labeled with 111In using benzyl-diethylenetriaminepentaacetic acid and with 125I using p-iodobenzoate. Affinity and cellular retention of conjugates were evaluated in vitro. Biodistribution of radiolabeled Affibody molecules was compared in mice bearing EGFR-expressing A431 xenografts. Specificity of EGFR targeting was confirmed by comparison with biodistribution of non–EGFR-specific counterparts. Results: Head-to-tail dimerization of the Affibody molecule improved the dissociation rate. In vitro, dimeric forms demonstrated superior cellular retention of radioactivity. For both molecular set-ups, retention was better for the 111In-labeled tracer than for the radioiodinated counterpart. In vivo, all conjugates accumulated specifically in xenografts and in EGFR-expressing tissues. The retention of radioactivity in tumors was better in vivo for dimeric forms; however, the absolute uptake values were higher for monomeric tracers. The best tracer, 111In-labeled ZEGFR:1907, provided a tumor-to-blood ratio of 100 (24 h after injection). Conclusion: The radiometal-labeled monomeric Affibody molecule ZEGFR:1907 has a potential for radionuclide molecular imaging of EGFR expression in malignant tumors.Keywords
This publication has 26 references indexed in Scilit:
- Affibody molecules: potential forin vivoimaging of molecular targets for cancer therapyExpert Opinion on Biological Therapy, 2007
- Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibodyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody MoleculeCancer Research, 2006
- PanitumumabDrugs of Today, 2006
- Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptorCurrent Oncology Reports, 2005
- Pharmacological background of EGFR targetingAnnals of Oncology, 2004
- Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2001
- Cellular processing of 125I- and 111in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cellsNuclear Medicine and Biology, 2000
- Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinomaNuclear Medicine and Biology, 1999
- In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425Cancer Immunology, Immunotherapy, 1996